Agenzia Italiana del Farmaco
VAXZEVRIA/COVID-19 Vaccine AstraZeneca: contraindication in individuals with previous capillary leak syndrome - VAXZEVRIA/COVID-19 Vaccine AstraZeneca: contraindication in individuals with previous capillary leak syndrome
VAXZEVRIA/COVID-19 Vaccine AstraZeneca: contraindication in individuals with previous capillary leak syndrome
The Italian Medicines Agency would like to inform you of the following:
- Very rare cases of capillary leak syndrome (CLS) have been reported in the first days after vaccination with Vaxzevria. A history of CLS was apparent in some of the cases. A fatal outcome has been reported.
- Vaxzevria is now contraindicated in individuals who have previously experienced episodes of CLS.
CLS is characterised by acute episodes of oedema mainly affecting the limbs, hypotension, haemoconcentration and hypoalbuminaemia. Patients with an acute episode of CLS following vaccination require prompt recognition and treatment. Intensive supportive therapy is usually warranted.
Published on: 23 June 2021
Una legislazione farmaceutica moderna è fondamentale per accompagnare l'#innovazione e garantire ai ...
Vai al post →
Si conclude la campagna #MedSafetyWeek di quest’anno! 🎉
Grazie per aver seguito i nostri canali in...
Vai al post →
Se sei un professionista sanitario, cogli l’occasione per discutere e individuare gli effetti indesi...
Vai al post →
💬 Ti è mai capitato di pensare “è solo un’eruzione cutanea”, “sono soltanto stressato” o “probabilm...
Vai al post →
Esistono diversi tipi di effetti indesiderati dei #farmaci: il modo in cui si manifestano può dipend...
Vai al post →
📍 A Roma la seconda edizione del Policy & Business Forum del Gruppo Editoriale @urania.news, import...
Vai al post →
